atai Life Sciences to Participate in Upcoming Investor Conferences
atai Life Sciences (NASDAQ: ATAI), a clinical-stage biopharmaceutical company focused on mental health treatments, has announced its participation in two upcoming investor conferences in June 2025. The company will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5 at 9:55 A.M. EDT in New York. Additionally, atai will present at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference through a pre-recorded fireside chat on June 17 at 7:00 A.M. EDT in a virtual format. Both presentations will be available via webcast on the company's investor relations website, with replays available after the events.
atai Life Sciences (NASDAQ: ATAI), un'azienda biofarmaceutica in fase clinica specializzata in trattamenti per la salute mentale, ha annunciato la sua partecipazione a due conferenze per investitori previste per giugno 2025. La società prenderà parte a una chiacchierata informale al Jefferies Global Healthcare Conference il 5 giugno alle 9:55 EDT a New York. Inoltre, atai presenterà al H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference tramite una chiacchierata preregistrata il 17 giugno alle 7:00 EDT in formato virtuale. Entrambe le presentazioni saranno disponibili in webcast sul sito web delle relazioni con gli investitori della società, con repliche accessibili dopo gli eventi.
atai Life Sciences (NASDAQ: ATAI), una compañía biofarmacéutica en etapa clínica centrada en tratamientos de salud mental, ha anunciado su participación en dos próximas conferencias para inversores en junio de 2025. La empresa participará en una charla informal en la Jefferies Global Healthcare Conference el 5 de junio a las 9:55 A.M. EDT en Nueva York. Además, atai presentará en la H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference mediante una charla pregrabada el 17 de junio a las 7:00 A.M. EDT en formato virtual. Ambas presentaciones estarán disponibles vía webcast en el sitio web de relaciones con inversores de la compañía, con repeticiones accesibles después de los eventos.
atai Life Sciences (NASDAQ: ATAI)는 정신 건강 치료에 중점을 둔 임상 단계 바이오제약 회사로, 2025년 6월에 열리는 두 개의 투자자 컨퍼런스에 참여할 것임을 발표했습니다. 회사는 6월 5일 오전 9시 55분 EDT에 뉴욕에서 열리는 Jefferies Global Healthcare Conference에서 파이어사이드 채팅에 참여할 예정입니다. 또한, atai는 6월 17일 오전 7시 EDT에 가상 형식으로 진행되는 H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference에서 사전 녹화된 파이어사이드 채팅을 통해 발표할 예정입니다. 두 발표 모두 회사의 투자자 관계 웹사이트를 통해 웹캐스트로 제공되며, 행사 후 재시청이 가능합니다.
atai Life Sciences (NASDAQ : ATAI), une société biopharmaceutique en phase clinique spécialisée dans les traitements de la santé mentale, a annoncé sa participation à deux conférences pour investisseurs prévues en juin 2025. L'entreprise participera à une discussion informelle lors de la Jefferies Global Healthcare Conference le 5 juin à 9h55 EDT à New York. De plus, atai présentera lors de la H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference à travers une discussion informelle préenregistrée le 17 juin à 7h00 EDT en format virtuel. Les deux présentations seront disponibles en webdiffusion sur le site des relations investisseurs de la société, avec des rediffusions accessibles après les événements.
atai Life Sciences (NASDAQ: ATAI), ein biopharmazeutisches Unternehmen in der klinischen Phase mit Schwerpunkt auf Behandlungen im Bereich der psychischen Gesundheit, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im Juni 2025 angekündigt. Das Unternehmen wird am 5. Juni um 9:55 Uhr EDT in New York an einem Fireside-Chat auf der Jefferies Global Healthcare Conference teilnehmen. Zusätzlich wird atai am 17. Juni um 7:00 Uhr EDT im Rahmen der H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference eine vorab aufgezeichnete Fireside-Chat-Präsentation in virtueller Form halten. Beide Präsentationen werden per Webcast auf der Investor-Relations-Website des Unternehmens verfügbar sein, mit Wiedergabemöglichkeiten nach den Veranstaltungen.
- None.
- None.
NEW YORK and BERLIN, May 29, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, today announced that the Company’s management team is scheduled to participate in the following investor conferences in June:
Jefferies Global Healthcare Conference
- Format: Fireside Chat
- Date and Time: Thursday, June 5 at 9:55 A.M. EDT
- Location: New York
- Webcast link: here
H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
- Format: Pre-recorded Fireside Chat
- Date and Time: Tuesday, June 17 at 7:00 A.M. EDT
- Location: Virtual
- Webcast link: here
The webcasts of the fireside chats will also be available on the Investors section of the atai website under Events. A replay will be available following the live event.
About atai Life Sciences
atai is a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes. Our pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder, which are in Phase 2 clinical development. We are also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD. These programs aim to address the complex nature of mental health providing commercially scalable interventional psychiatry therapies that can integrate seamlessly into healthcare systems. For the latest updates and to learn more about our mission, visit www.atai.com or follow us on LinkedIn.
Contact Information
Investor Contact:
IR@atai.com
Media Contact:
PR@atai.com
FAQ
When is ATAI presenting at the Jefferies Global Healthcare Conference 2025?
What type of company is ATAI Life Sciences?
Where can investors watch ATAI's conference presentations?
When is ATAI's presentation at the H.C. Wainwright Neuro Conference 2025?
